Postoperative adjuvant treatments for biliary tract cancer
- 1 September 2008
- journal article
- Published by Springer Science and Business Media LLC in Journal of Hepato-Biliary-Pancreatic Surgery
- Vol. 15 (5), 463-467
- https://doi.org/10.1007/s00534-008-1358-2
Abstract
Surgery currently remains the only potentially curative treatment for biliary tract cancer, and most patients develop recurrence. Thus, effective adjuvant therapy is required to increase the curability of surgery and to prolong the survival in these patients. However, to date, no standard postoperative adjuvant therapy regimen has been established for patients with biliary tract cancer. Based on favorable results reported from phase II trials, gemcitabine and S-1 are currently available as promising agents for the treatment of unresectable biliary tract cancer in Japan. Both agents are also expected to be effective in the postoperative adjuvant therapy setting for biliary tract cancer, and well-designed randomized controlled trials (phase III trials) to determine the efficacy of these agents in the postoperative adjuvant setting should be pursued vigorously. In phase III trials, appropriate stratification of patients is important, and the primary disease (gallbladder cancer versus nongallbladder cancers), curability (R0 or R1), and presence/absence of lymph node metastasis should be taken into account.Keywords
This publication has 44 references indexed in Scilit:
- Phase II study of single-agent gemcitabine in patients with advanced biliary tract cancerCancer Chemotherapy and Pharmacology, 2005
- Phase II trial of weekly 24-hour infusion of gemcitabine in patients with advanced gallbladder and biliary tract carcinomaBMC Cancer, 2005
- Single-agent Gemcitabine in the Treatment of Advanced Biliary Tract Cancers: a Phase II StudyJapanese Journal of Clinical Oncology, 2005
- Cancer Statistics, 2005CA: A Cancer Journal for Clinicians, 2005
- A Phase II Trial of Fixed Dose Rate Gemcitabine in Patients With Advanced Biliary Tree CarcinomaAmerican Journal of Clinical Oncology, 2004
- Weekly Gemcitabine for the Treatment of Biliary Tract and Gallbladder CancerInvestigational New Drugs, 2004
- Biliary tract cancer treatment: results from the Biliary Tract Cancer Statistics Registry in JapanJournal of Hepato-Biliary-Pancreatic Surgery, 2002
- Phase II trial of two-weekly gemcitabine in patients with advanced biliary tract cancerAnnals Of Oncology, 2001
- Aggressive preoperative management and extended surgery for hilar cholangiocarcinoma: Nagoya experienceJournal of Hepato-Biliary-Pancreatic Surgery, 2000
- What constitutes long term survival after surgery for hilar cholangiocarcinoma?Cancer, 1997